From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC

Hongyu Liu

doi:10.54097/0trsfx05

Authors

Hongyu Liu

DOI:

https://doi.org/10.54097/0trsfx05

Keywords:

EGFR, KRAS, ALK, NSCLC, Resistance mechanisms, Targeted therapy, Therapeutic strategy.

Abstract

Apart from the genetic mutations in mutant EGFR and KRAS, and ALK fusion gene that characterize NSCLC, several other genetic mutations also distinguish NSCLC. The paper reviews the pathogenic mechanisms of these gene alterations and the principles generalized for new generations of agents against EGFR, KRAS, and ALK TKIs. Ways to future reduce resistance comprise new inhibitor designs and combinations, as well as approaches for early detection such as liquid biopsy. The focus is on those advances serving to increase the durability of targeted therapies and better patient outcomes in NSCLC.

Downloads

Download data is not yet available.

References

[1] Siegel RL, Giaquinto AN, Jemal A: Cancer statistics, 2024. CA Cancer J Clin 74: 12 - 49, 2024.

[2] Blandin Knight S, Crosbie PA, Balata H, et al: Progress and prospects of early detection in lung cancer. Open Biol 7, 2017.

[3] Boumahdi S, de Sauvage FJ: The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 19: 39 - 56, 2020.

[4] Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. Embo j 19: 3159 - 67, 2000.

[5] Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24 - 31, 200.

[6] He J, Huang Z, Han L, et al: Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). Int J Oncol 59, 2021.

[7] Westover D, Zugazagoitia J, Cho BC, et al: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29: i10 - i19, 2018.

[8] Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380 - 8, 2010.

[9] Cross DA, Ashton SE, Ghiorghiu S, et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046 - 61, 2014.

[10] Fu K, Xie F, Wang F, Fu L: Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol 15: 173, 2022.

[11] Passaro A, Guerini-Rocco E, Pochesci A, et al: Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res 117: 406 - 415, 2017.

[12] Thress KS, Paweletz CP, Felip E, et al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21: 560 - 2, 2015.

[13] Reck M, Carbone DP, Garassino M, Barlesi F: Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32: 1101 - 1110, 2021.

[14] Veluswamy R, Mack PC, Houldsworth J, et al: KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing. J Mol Diagn 23: 507 - 520, 2021.

[15] Harada G, Yang SR, Cocco E, Drilon A: Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol 20: 229 - 249, 2023.

[16] Ostrem JM, Shokat KM: Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov 15: 771 - 785, 2016.

[17] Canon J, Rex K, Saiki AY, et al: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575: 217 - 223, 2019.

[18] Jänne PA, Riely GJ, Gadgeel SM, et al: Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med 387: 120 - 131, 2022.

[19] Scheffler M, Ihle MA, Hein R, et al: K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. J Thorac Oncol 14: 606 - 616, 2019.

[20] Arbour KC, Jordan E, Kim HR, et al: Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24: 334 - 340, 2018.

[21] Socinski MA, Jotte RM, Cappuzzo F, et al: Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378: 2288 - 2301, 2018.

[22] Bange E, Marmarelis ME, Hwang W-T, et al: Impact of KRAS and TP53 co-mutations on outcomes after first-line systemic therapy among patients with STK11-mutated advanced non–small-cell lung cancer. JCO precision oncology 3: 1 - 11, 2019.

[23] Ahrendt SA, Hu Y, Buta M, et al: p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 95: 961 - 70, 2003.

[24] Janne P, Rybkin II, Spira A, et al: KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRAS G12C mutation from a phase 1/2 study, 32nd EORTC NCI AACR symposium, 2020.

[25] Popow J, Farnaby W, Gollner A, et al: Targeting cancer with small-molecule pan-KRAS degraders. Science 385: 1338 - 1347, 2024.

[26] Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama 311: 1998 - 2006, 2014.

[27] Ou SI, Zhu VW, Nagasaka M: Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 1:100015, 2020.

[28] Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561 - 6, 2007.

[29] Hrustanovic G, Olivas V, Pazarentzos E, et al: RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med 21: 1038 - 47, 2015.

[30] Yang L, Li G, Zhao L, et al: Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. Tumour Biol 35: 9759 - 67, 2014.

[31] Li Y, Li Y, Zhang H, et al: EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. BMC Pulm Med 21: 190, 2021.

[32] Schneider JL, Lin JJ, Shaw AT: ALK-positive lung cancer: a moving target. Nat Cancer 4: 330 - 343, 2023.

[33] Peters S, Camidge DR, Shaw AT, et al: Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377: 829 - 838, 2017.

[34] Awad MM, Shaw AT: ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12: 429 - 39, 2014.

[35] Dagogo-Jack I, Yoda S, Lennerz JK, et al: MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res 26: 2535 - 2545, 2020.

[36] Tanizaki J, Okamoto I, Okabe T, et al: Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 18: 6219 - 26, 2012.

[37] Akamine T, Toyokawa G, Tagawa T, Seto T: Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. Onco Targets Ther 11: 5093 - 5101, 2018.

[38] Zou HY, Li Q, Engstrom LD, et al: PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A 112: 3493 - 8, 2015.

[39] Solomon BJ, Besse B, Bauer TM, et al: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 19: 1654 - 1667, 2018.

[40] Tan AC, Tan DSW: Targeted Therapies for Lung Cancer Patients with Oncogenic Driver Molecular Alterations. J Clin Oncol 40: 611 - 625, 2022.

[41] Lin JJ, Chin E, Yeap BY, et al: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 14: 135 - 140, 2019.

[42] Song Z, Liu Y: [Progress of Liquid Biopsy in Early Diagnosis of Lung Cancer]. Zhongguo Fei Ai Za Zhi 21: 620 - 627, 2018.

[43] Gouda MA, Janku F, Wahida A, et al: Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol 35: 267 - 275, 2024.

[44] Nikanjam M, Kato S, Kurzrock R: Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15: 131, 2022.

[45] Batool SM, Yekula A, Khanna P, et al: The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep Med 4: 101198, 2023.